Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported second quarter EPS of $-1.31, $0.26 worse than the analyst estimate of $-1.05. Revenue for the quarter came in at $249K versus the consensus estimate of $7.61M.
Cytokinetics Inc's stock price closed at $54.00. It is down -13.04% in the last 3 months and up 66.20% in the last 12 months.
Cytokinetics Inc saw 9 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Cytokinetics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Cytokinetics Inc's Financial Health score is "weak performance".
Check out Cytokinetics Inc's recent earnings performance, and Cytokinetics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar